Ginkgo Bioworks Holdings, Inc. (DNA)

Market Cap	332.72M
Revenue (ttm)	227.04M
Net Income (ttm)	-547.03M
Shares Out	54.37M
EPS (ttm)	-10.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,407,772
Open	6.54
Previous Close	6.59
Day's Range	6.11 - 6.57
52-Week Range	5.26 - 47.60
Beta	1.24
Analysts	Sell
Price Target	17.25 (+181.86%)
Earnings Date	May 8, 2025

About DNA

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 834
• Stock Exchange: NYSE
• Ticker Symbol: DNA
• Website: https://www.ginkgo.bio

Financial Performance

In 2024, Ginkgo Bioworks Holdings's revenue was $227.04 million, a decrease of -9.71% compared to the previous year's $251.46 million. Losses were -$547.03 million, -38.73% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for DNA stock is "Sell." The 12-month stock price forecast is $17.25, which is an increase of 181.86% from the latest price.

Price Target

$17.25

(181.86% upside)

Analyst Consensus: Sell